Singapore has a chance to shine in precision medicine
Existing research capabilities and support for new startups can drive growth in this field
Add BT as a preferred source
IMAGINE if the medicine prescribed to you could be tailored to your genetic makeup. This would prevent instances of drugs having no effect – or worse, making you sicker.
With precision medicine, this is not merely a matter of imagination. Nalagenetics, a spin-off of the Agency for Science, Technology and Research (A*Star), aims to do just this.
The company is working with the National University Hospital and Raffles Medical Group on something called “pre-emptive pharmacogenomics”. This involves understanding a patient’s genomic profile and cross-checking it with biomarkers, to pre-emptively flag any issues with medication.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Inside Indonesia’s trial of Gojek co-founder: How a Google laptop deal became a multitrillion-rupiah case
No prosecution for Seatrium over Brazilian corruption offences, High Court approves US$110 million penalty
Will the Philippines hit the brakes on a deregulated oil industry amid fuel pain?
Hao Mart shuts stores, sinks deeper into losses with four High Court lawsuits looming
